Effects of selective nitric oxide synthase inhibition on IGF-1, caspases and cytokines in a newborn piglet model of perinatal hypoxia-ischaemia

Dev Neurosci. 2002;24(5):396-404. doi: 10.1159/000069045.

Abstract

Selective inhibition of neuronal and inducible nitric oxide synthase (NOS) with 2-iminobiotin previously showed a reduction in brain cell injury. In the present study, we investigated the effects of 2-iminobiotin treatment on insulin-like growth factor-1 (IGF-1) expression, caspase activity and cytokine expression in a newborn piglet model of perinatal hypoxia-ischaemia. Newborn piglets were subjected to 1 h of hypoxia-ischaemia and were treated intravenously with vehicle or 2-iminobiotin. Vehicle-treated piglets showed reduced IGF-1 mRNA expression and increased caspase-3 activity and DNA fragmentation. 2-Iminobiotin treatment, administered immediately upon reperfusion, prevented these observations. No differences in caspase-8 and -9 activity and cytokine [interleukin (IL)-1alpha/beta, IL-6, tumour necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta] mRNA expression were demonstrated between vehicle- and 2-iminobiotin-treated piglets at 24 h following hypoxia-ischaemia. IGF-1 mRNA correlated inversely with caspase-3 and transferase-mediated dUTP-biotin in situ nick end labelling score in the cortex, but positively with caspase-8. Cytokine mRNA did not correlate with IGF-1 mRNA, caspase-3 activity or DNA fragmentation. The present results indicate that the previously demonstrated neuroprotective effect of 2-iminobiotin treatment after perinatal hypoxia-ischaemia coincided with a preservation of the endogenous IGF-1 production and reduced caspase-3 activity, but not with a significant decrease in cytokine production.

MeSH terms

  • Animals
  • Animals, Newborn
  • Biotin / analogs & derivatives*
  • Biotin / pharmacology*
  • Brain / drug effects*
  • Brain / metabolism
  • Brain / pathology
  • Caspases / metabolism
  • Cytokines / metabolism
  • DNA Fragmentation / drug effects
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Hypoxia-Ischemia, Brain / metabolism*
  • In Situ Nick-End Labeling
  • Insulin-Like Growth Factor I / biosynthesis
  • Models, Animal
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • Primed In Situ Labeling
  • RNA, Messenger / analysis
  • Swine

Substances

  • Cytokines
  • Enzyme Inhibitors
  • RNA, Messenger
  • Insulin-Like Growth Factor I
  • Biotin
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type I
  • Nitric Oxide Synthase Type II
  • Caspases
  • 2-iminobiotin